Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study

Published:2016-10-07 Issue:11-12 Volume:44 Page:1199-1212
ISSN:0269-2813
Container-title:Alimentary Pharmacology & Therapeutics
language:en
Short-container-title:Aliment Pharmacol Ther

Author:

Stallmach A.¹,Langbein C.¹,Atreya R.²,Bruns T.¹^ORCID,Dignass A.³,Ende K.⁴,Hampe J.⁵,Hartmann F.³,Neurath M. F.²,Maul J.⁶,Preiss J. C.⁶,Schmelz R.⁵,Siegmund B.⁶,Schulze H.³,Teich N.⁷,von Arnim U.⁸,Baumgart D. C.⁶,Schmidt C.¹

Affiliation:

1. Jena Germany

2. Erlangen Germany

3. Frankfurt/Main Germany

4. Erfurt Germany

5. Dresden Germany

6. Berlin Germany

7. Leipzig Germany

8. Magdeburg Germany

Publisher

Wiley

Subject

Pharmacology (medical),Gastroenterology,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/apt.13813/fullpdf

Reference35 articles.

1. Recent trends in the epidemiology of inflammatory bowel diseases: up or down?;Lakatos;World J Gastroenterol,2006

2. Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial;Hanauer;Lancet,2002

3. Infliximab for induction and maintenance therapy for ulcerative colitis;Rutgeerts;N Engl J Med,2005

4. Certolizumab pegol for the treatment of Crohn's disease;Sandborn;N Engl J Med,2007

5. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial;Colombel;Gastroenterology,2007

Cited by 147 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-world effectiveness and safety of advanced therapies for the treatment of moderate-to-severe ulcerative colitis: Evidence from a systematic literature review;Journal of Managed Care & Specialty Pharmacy;2024-09

2. Selective granulocyte–monocyte apheresis during induction with vedolizumab in moderate–severe ulcerative colitis: Experience in a tertiary hospital;Gastroenterología y Hepatología;2024-08

3. Selective granulocyte–monocyte apheresis during induction with vedolizumab in moderate–severe ulcerative colitis: Experience in a tertiary hospital;Gastroenterología y Hepatología (English Edition);2024-08

4. Approach to loss of response to advanced therapies in inflammatory bowel disease;World Journal of Gastroenterology;2024-06-14

5. Aktualisierte S3-Leitlinie Colitis ulcerosa (Version 6.2);Zeitschrift für Gastroenterologie;2024-05

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3